Topical timolol for superficial cutaneous infantile hemangiomas in very preterm infants

Aleksandra Matić; Sonja Prćić; Milan Matić

doi:10.2298/VSP190219112M

Aleksandra Matić University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia
Sonja Prćić University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia
Milan Matić University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia

DOI: https://doi.org/10.2298/VSP190219112M

Keywords: hemangioma;, skin neoplasms;, timolol;, administration, topical;, child;, infant, premature;, treatment, outcome.

Abstract

Introduction. Infantile hemangiomas (IHs) occur 3 to 4 times more frequently in preterm infants than in those born at term. Yet, data about efficacy and safety of topical therapy for IHs in preterm infants, especially in those born with very low gestational age (less than 33 gestational weeks) is very scarce. Case report. We reported five very preterm girls treated with topical timolol maleate 0.5% gel for superficial cutaneous IHs. In four infants topical timolol was applied on a single IH each, and in one infant two IHs were treated. Out of six treated IHs, one was located on the face, four on the trunk and one on the leg. They were regularly monitored for IH involution and potential adverse effects of timolol for 6–13 months of local treatment. Good therapeutic effect was achieved in all the presented infants, with no adverse effects related to topical administration of timolol-maleate. Conclusion. Topical timolol is an effective and safe therapy for superficial cutaneous infantile hemangiomas in very preterm infants. The treatment should be discussed in detail with parents and individualized management plan should be tailored for each infant in order to maximize the chances of a successful outcome, while avoiding adverse effects.

References

Goelz R, Poets CF. Incidence and treatment of infantile hae-mangioma in preterm infants. Arch Dis Child Fetal Neonatal Ed 2015; 100: 85–91.

Garzon MC, Drolet BA, Baselga E, Chamlin SL, Haggstrom AN, Horii K, et al. Comparison of Infantile Hemangiomas in Pre-term and Term Infants: A Prospective Study. Arch Dermatol 2008; 144(9): 1231‒2.

Munden A, Butschek R, Tom WL, Marshall JS, Poeltler DM, Krohne SE, et al. Prospective study of infantile hemangiomas: Incidence, clinical characteristics, and association with placen-tal anomalies. Br J Dermatol 2014; 170(4): 907‒13.

Janmohamed SR, de Waard-van der Spek FB, Madern GC, de Laat PC, Hop WC, Oranje AP. Scoring the proliferative activity of haemangioma of infancy: the Haemangioma Activity Score (HAS). Clin Exp Dermatol 2011;36(7):715-23

Leaute-Labreze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taieb A. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 358(24): 2649–51.

Guo S, Ni N. Topical treatment for capillary hemangioma of the eyelid using beta-blocker solution. Arch Ophthalmol 2010; 128(2): 255–6.

Vivas-Colmenares GV, Bernabeu-Wittel J, Alonso-Arroyo V, Matute de Cardenas JA, Fernandez-Pineda I. Effectiveness of Propranolol in the Treatment of Infantile Hemangioma Be-yond the Proliferation Phase. Pediatric Dermatology 2015; 32(3): 348‒52.

Hogeling M, Adams S, Wargon O. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics 2011; 128(2): e259‒66.

Zaher H, Rasheed H, Hegazy RA, Hegazy RA, Abdelhalim DM, Gawdat HI. Oral propranolol: an effective, safe treatment for infantile hemangiomas. Eur J Dermatol 2011; 21(4): 558‒63.

Zvulunov A, McCuaig C, Frieden IJ, Mancini AJ, Puttgen KB, Dohil M et al. Oral propranolol therapy for infantile hemangiomas beyond the proliferation phase: a multicenter retrospective study. Pediatr Dermatol 2011; 28(2): 94‒8.

Wu HW, Liu C, Wang X, Zhang L, Yuan W, Zheng JW, et al. Topical Application of 0.5% Timolol Maleate Hydrogel for the Treatment of Superficial Infantile Hemangioma. Front Oncol 2017; 7: 137.

Danarti R, Ariwibowo L, Radiono S, Budiyanto A. Topical Tim-olol Maleate 0.5% for Infantile Hemangioma: Its Effective-ness Compared to Ultrapotent Topical Corticosteroids – A Single-Center Experience of 278 Cases. Dermatology 2016; 232(2): 566‒71.

Moehrle M, Leaute-Labreze C, Schmidt V, Röcken M, Poets CF, Goelz R. Topical timolol for small hemangiomas of infancy. Pediatr Dermatol 2013; 30(2): 245–9.

Chan H, McKay C, Adams S, Wargon O. RCT of Timolol Male-ate Gel for Superficial Infantile Hemangiomas in 5- to 24-Week-Olds. Pediatrics 2013; 131(6): e1739‒47.

Yu L, Li S, Su B, Liu Z, Fang J, Zhu L, et al. Treatment of su-perficial infantile hemangiomas with timolol: Evaluation of short-term efficacy and safety in infants. Exp Ther Med 2013; 6(2): 388‒90.

Luu M, Frieden IJ. Haemangioma: clinical course, complica-tions and management. Br J Dermatol 2013; 169(1): 20‒30.

Drolet BA, Frommelt PC, Chamlin SL, Haggstrom A, Bauman NM, Chiu YE, et al. Initiation and use of propranolol for in-fantile hemangioma: report of a consensus conference. Pediat-rics 2013; 131(1): 128–40.

Couto RA, Maclellan RA, Zurakowski D, Greene AK. Infantile hemangioma: clinical assessment of the involuting phase and implications for management. Plast Reconstr Surg 2012; 130(3): 619–24.

Bauland CG, Luning TH, Smit JM, Zeebregts CJ, Spauwen PH. Untreated hemangiomas: growth pattern and residual lesions. Plast Reconstr Surg 2011; 127(4): 1643–8.

Theiler M, Hoffman WY, Frieden IJ. Breast Hypoplasia as a Complication of an Untreated Infantile Hemangioma. Pediatr Dermatol 2016; 33(2): e129‒30.

Zaher H, Rasheed H, Esmat S, Hegazy RA, Gawdat HI, Hegazy RA, et al. Propranolol and infantile hemangiomas: different routes of administration, a randomized clinical trial. Eur J Dermatol 2013; 23(5): 646–52.

Gan LQ, Ni SL, Tan Q, Wang H. A Retrospective Study of Propranolol Therapy in 109 Infants with Infantile Hemangio-ma. Pediatric Dermatol 2013; 30(2): 270‒2.

Schupp CJ, Kleber JB, Günther P, Holland-Cunz S. Propranolol Therapy in 55 Infants with Infantile Hemangioma: Dosage, Duration, Adverse Effects, and Outcome. Pediatr Dermatol 2011; 28(6): 640‒4.

Bonifazi E, Acquafredda A, Milano A, Montagna O, Laforgia N. Severe Hypoglycemia During Successful Treatment of Diffuse Hemangiomatosis with Propranolol. Pediatr Dermatol 2010; 27(2): 195‒6.

Langley A, Pope E. Propranolol and central nervous system function: potential implications for paediatric patients with infantile haemangiomas. Br J Dermatol 2015; 172(1): 13–23.

Gonzalez-Llorente N, del Olmo-Benito I, Munoz-Ollero N, Descalzo MA, Garcia-Doval I, Torrelo A. Study of Cognitive Function in Children Treated with Propranolol for Infantile Hemangioma. Pediatr Dermatol 2017; 34(5): 554‒8.

Semkova K, Marina S, Kazandjieva J. Topical treatment of infan-tile hemangiomas – where are we now? Serb J Dermatol Vene-reol 2011; 3(4): 145‒52.

Ng MSY, Tay YK, Ng SS, Foong AYW, Koh MJ. Comparison of Two Formulations of Topical Timolol for the Treatment of Infantile Hemangiomas. Pediatr Dermatol 2017; 34(4): 492‒3.

Frommelt P, Juern A, Siegel D, Holland K, Seefeldt M, Yu J, et al. Adverse Events in Young and Preterm Infants Receiving Top-ical Timolol for Infantile Hemangioma. Pediatr Dermatol 2016; 33(4): 405‒14.